Rallybio Corporation (the “Company”) is a clinical-stage biopharmaceutical company developing therapies for patients with severe and rare disorders. The Company is targeting diseases with known pathophysiology, a clear correlation between biology and clinical outcomes and an epidemiology of greater than 3 patients per million. The Company’s lead asset, RLYB212, is a preclinical monoclonal anti-human platelet antigen 1-a (HPA-1a) antibody for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.